

16 February 2026

## Strength Priced In

Fortis Healthcare (FORH IN) Q3FY26 revenue and EBITDA were broadly in line with our estimates, but PAT came below by 4% as higher D&A and finance cost hurt. The hospitals segment performance remains strong with 19% YoY growth and 170bp YoY margin expansion. Additional revenue from operations & management (O&M) agreement with Gleneagles Hospital may have lifted margin. The diagnostics segment revenue growth remains unimpressive at 8.5% YoY, but EBITDA margin was strong at 23%, up 900bps YoY. Management retained FY26 target for both segments and indicated room for further growth and margin expansion in FY27; we have already built this into our estimates. We keep our FY26-FY28 EBITDA and core EPS estimates broadly unchanged. We downgrade our rating to **Reduce**, as we see limited upside after ~50% stock price performance in the past year. We keep our TP unchanged at INR 927.

**Growth and margin expansion continues in the hospitals segment:** Revenue and EBITDA from the hospitals segment grew at ~19.4% YoY and 29.2% YoY, respectively, in Q3FY26. Average rate per operating bed (ARPOB) growth of 6% and addition of beds at Manesar and Jalandhar bolstered top-line growth. EBITDA growth was aided further by a 170bp margin improvement YoY, in line with guidance. Additional revenue from the O&M agreement with Gleneagles Hospital may have lifted margin.

**Bed additions, Gleneagles deal add to growth but largely priced in:** FORH plans to add ~900 beds to its operations in FY27, including some in flagship FMRI facility. Ramp-up of these beds add to growth visibility in FY27. FORH recently signed an O&M contract involving five hospitals from its sister concern – Gleneagles. Revenue fees of 3% from these facilities would add to growth. Management expects room for further margin expansion in FY27, given the bed additions are mostly Brownfield in facilities that are doing well. However, we have already factored in most into our estimates and discounted the stock price, accordingly.

**Growth likely to pick up in the diagnostics segment:** EBITDA margin of 23% in Q3FY26 came in line with management's full-year target. Revenue growth of 8.5% YoY in Q3 still needs to pick up to meet guidance of double-digit growth in FY26. Rebranding exercise-related issues and associated marketing cost dragged growth and profitability in the diagnostics segment in FY25. However, those issues are behind us, and margin should improve hereafter. FORH has recently acquired the erstwhile SRL brand and management believes this will help further in customer acquisition and growth.

**Downgrade to Reduce with an unchanged TP of INR 927:** We keep our FY26-28E EBITDA and core EPS estimates broadly unchanged. FORH trades at 53x FY27E core P/E and 30x FY27E EV/EBITDA (pre-IndAS). We keep our TP unchanged at INR 927 on 44.8x FY27E core P/E plus cash per share. We see limited upside after ~50% stock price performance in the past year. Hence, we downgrade our rating to **Reduce** from Accumulate. Value accretive deals with promoter companies or their associates are key risks to our call.

### Key financials

YE March (INR mn)	FY24	FY25	FY26E	FY27E	FY28E
Revenue (INR mn)	68,929	77,828	91,172	105,216	116,544
YoY (%)	9.5	12.9	17.1	15.4	10.8
EBITDA (INR mn)	12,676	15,879	21,102	24,945	28,039
EBITDA margin (%)	18.4	20.4	23.1	23.7	24.1
Adj PAT (INR mn)	5,829	8,636	10,565	13,467	16,047
YoY (%)	1.7	29.3	35.2	28.7	19.2
Fully DEPS (INR)	7.7	11.4	14.0	17.8	21.3
RoE (%)	6.2	8.7	10.9	12.5	13.9
RoCE (%)	9.1	10.5	13.7	15.4	17.2
P/E (x)	118.7	80.1	65.5	51.4	43.1
EV/EBITDA (x)	57.0	45.5	34.2	29.0	25.8

Note: Pricing as on 16 February 2026; Source: Company, Elara Securities Estimate

Rating: **Reduce**

Target Price: **INR 927**

Upside: **1%**

CMP: **INR 917**


As on 16 February 2026

#### Key data

Bloomberg	FORH IN
Reuters Code	FOHE.NS
Shares outstanding (mn)	755
Market cap (INR bn/USD mn)	692/7,636
EV (INR bn/USD mn)	722/7,970
ADTV 3M (INR mn/USD mn)	2,712/30
52 week high/low	1,105/521
Free float (%)	69

Note: as on 16 February 2026; Source: Bloomberg

#### Price chart



Source: Bloomberg

	Q4 FY25	Q1 FY26	Q2 FY26	Q3 FY26
Shareholding (%)				
Promoter	31.2	31.2	31.2	31.2
% Pledge	0.0	0.0	0.0	0.0
FII	27.4	27.2	27.9	27.8
DII	29.5	29.8	29.1	29.3
Others	11.9	11.9	11.8	11.7

Source: BSE

Price performance (%)	3M	6M	12M
Nifty	(1.7)	3.4	11.1
Fortis Healthcare	(2.2)	(1.6)	51.8
NSE Mid-cap	(1.8)	3.8	15.5
NSE Small-cap	(6.4)	(4.0)	10.3

Source: Bloomberg

#### Dr Bino Pathiparampil

Healthcare, Pharmaceuticals, Strategy

+91 22 6164 8572  
bino.pathiparampil@elaracapital.com

Associate  
Kashish Thakur  
kashish.thakur@elaracapital.com

Shivam Agarwal  
shivam.agarwal@elaracapital.com



## Financials (YE March)

Income Statement (INR mn)	FY24	FY25	FY26E	FY27E	FY28E
Total Revenue	68,929	77,828	91,172	105,216	116,544
Gross Profit	52,742	59,526	70,071	80,776	89,447
EBITDA	12,676	15,879	21,102	24,945	28,039
EBIT	9,251	12,023	16,608	20,143	22,996
Interest expense	1,310	1,844	3,105	2,492	1,869
Other income	383	669	583	583	583
Exceptional/ Extra-ordinary items	160	(893)	(98)	-	-
PBT	8,485	9,955	13,988	18,234	21,710
Tax	2,128	1,977	3,405	4,558	5,427
Minority interest/Associates income	(368)	(237)	(116)	(209)	(235)
Reported PAT	5,989	7,742	10,467	13,467	16,047
Adjusted PAT	5,829	8,636	10,565	13,467	16,047

FY26 margin is set to be at ~23%

Balance Sheet (INR mn)	FY24	FY25	FY26E	FY27E	FY28E
Shareholders' Equity	96,820	89,165	98,761	111,264	113,818
Minority Interest	8,932	2,529	2,645	2,853	2,880
Trade Payables	7,278	8,076	9,109	10,435	11,506
Provisions & Other Current Liabilities	3,058	6,901	4,204	4,816	5,310
Total Borrowings	8,583	21,953	27,380	19,400	17,505
Other long term liabilities	8,216	8,291	8,291	8,291	8,291
<b>Total liabilities &amp; equity</b>	<b>132,888</b>	<b>136,915</b>	<b>150,390</b>	<b>157,060</b>	<b>159,310</b>
Net Fixed Assets	58,080	62,521	67,587	72,918	73,278
Goodwill	41,942	41,942	41,942	41,942	41,942
Intangible assets	4,135	3,841	13,141	13,141	13,141
Business Investments / other NC assets	14,526	13,899	13,899	13,899	13,899
Cash, Bank Balances & treasury investments	6,000	5,097	1,969	1,483	1,900
Inventories	1,074	1,153	1,823	2,104	2,331
Sundry Debtors	6,278	7,845	8,206	9,469	10,489
Other Current Assets	854	618	1,823	2,104	2,331
<b>Total Assets</b>	<b>132,888</b>	<b>136,915</b>	<b>150,390</b>	<b>157,060</b>	<b>159,310</b>

Cash Flow Statement (INR mn)	FY24	FY25	FY26E	FY27E	FY28E
<b>Cashflow from Operations</b>	<b>11,001</b>	<b>14,239</b>	<b>12,629</b>	<b>19,177</b>	<b>21,411</b>
Capital expenditure	(9,280)	(8,296)	(8,794)	(9,321)	(9,881)
Acquisitions / divestitures	1,480	(1,778)	(9,300)	-	-
Other Business cashflow	-	(42)	-	-	-
<b>Free Cash Flow</b>	<b>3,201</b>	<b>4,123</b>	<b>(5,465)</b>	<b>9,856</b>	<b>11,530</b>
Cashflow from Financing	(845)	(5,026)	2,337	(10,342)	(11,113)
Net Change in Cash / treasury investments	2,356	(902)	(3,128)	(486)	417

Key assumptions & Ratios	FY24	FY25	FY26E	FY27E	FY28E
Dividend per share (INR)	1.0	1.0	1.0	1.0	1.0
Book value per share (INR)	128.2	118.1	130.8	147.4	150.8
RoCE (Pre-tax) (%)	9.1	10.5	13.7	15.4	17.2
ROIC (Pre-tax) (%)	9.6	11.1	14.1	15.6	17.4
ROE (%)	6.2	8.7	10.9	12.5	13.9
Asset Turnover (x)	1.3	1.3	1.4	1.5	1.6
Net Debt to Equity (x)	0.0	0.2	0.3	0.2	0.1
Net Debt to EBITDA (x)	0.2	1.1	1.2	0.7	0.6
Interest cover (x) (EBITDA/ int exp)	9.7	8.6	6.8	10.0	15.0
Total Working capital days (WC/rev)	21.4	(1.3)	2.2	(0.3)	0.8

Valuation	FY24	FY25	FY26E	FY27E	FY28E
P/E (x)	118.7	80.1	65.5	51.4	43.1
P/Sales (x)	10.0	8.9	7.6	6.6	5.9
EV/ EBITDA (x)	57.0	45.5	34.2	29.0	25.8
EV/ OCF (x)	65.7	50.7	57.2	37.7	33.7
FCF Yield	0.4	0.6	(0.8)	1.4	1.6
Price to BV (x)	7.1	7.8	7.0	6.2	6.1
Dividend yield (%)	0.1	0.1	0.1	0.1	0.1

Note: Pricing as on 16 February 2026; Source: Company, Elara Securities Estimate

**Exhibit 1: Quarterly results**

YE March (INR mn)	Q3FY26	Q3FY25	YoY (%)	Q2FY26	QoQ (%)
Net Sales	22,650	19,283	17.5	23,314	(2.8)
Gross Profit	17,489	14,748	18.6	17,919	(2.4)
Gross Margin (%)	77.2	76.5	73.0	76.9	35.5
EBITDA	5,057	3,751	34.8	5,563	(9.1)
EBITDA Margin (%)	22.3	19.5	287.1	23.9	(153.8)
Other Income	83	209	(60.3)	226	(63.3)
Interest	857	452	89.9	749	14.5
Depreciation	1,201	973	23.4	1,058	13.5
PBT	3,081	2,535	21.5	3,982	(22.6)
Tax	683	251	172.1	966	(29.3)
Tax Rate (%)	22.2	9.9	1,226.8	24.3	(209.0)
PAT	2,398	2,284	5.0	3,016	(20.5)
Minority Interest	(1)	(43)	(96.8)	(32)	(95.7)
PAT	2,396	2,241	6.9	2,984	(19.7)
Adjusted Net Income	1,937	2,479	(21.9)	3,219	(39.8)
NPM (%)	8.6	12.9	(430.3)	13.8	(525.5)

Source: Company, Elara Securities Research

**Exhibit 2: Valuation based on core earnings**

	FY24	FY25	FY26E	FY27E	FY28E
Core EPS (INR)	7.3	10.7	13.4	17.3	20.7
Core EPS growth (%)	18.3	45.9	25.2	28.7	19.8
Cash per share (INR)	7.9	6.8	2.6	2.0	2.5
Current Core P/E (x)	123.3	84.5	67.5	52.5	43.8
Core ROIC (%)	11.0	11.1	15.3	15.9	18.1

Source: Company, Elara Securities Estimate

**Conference call highlights**
**Financial highlights**

- ▶ Consolidated revenue for Q3FY26 stood at ~INR 22.7bn, up 17.5% YoY, with operating EBITDA margin improving to 22.3% (vs. 19.4% in Q3FY25), supported by a richer case mix and the addition of new specialties in recent quarters.
- ▶ Exceptional item of INR 97.5mn includes INR 550mn on account of new Labor Code changes, which got offset by reversal of impairment on investment in an associate company.
- ▶ As on 31 December 2025, net debt stood at ~INR 25.5bn, translating to a net debt/EBITDA ratio of 1.24x, compared to 0.41x as on 31 December 2024 (based on annualized Q3 EBITDA).
- ▶ The rise in debt was primarily due to the funds raised to partly finance acquisition of the PE stake in Agilus Diagnostics and the acquisition of the Shrimann Hospital at Jalandhar, in Punjab, among other investments.
- ▶ During the quarter, FORH acquired a 100% stake in TMI Healthcare along with the underlying land and building, which currently operates 125-bed People Tree Hospital at Yeshwanthpur, in Bengaluru. Also, the adjacent land was acquired enabling future expansion to 300 beds. The total cost stood at INR 4.3bn.
- ▶ In November 2025, the company launched *Adayu*, a 36-bedded specialized mental health care facility at Gurugram, offering evidence-based treatments through a multidisciplinary approach to deliver comprehensive and compassionate care.

### Hospitals business

- ▶ Hospitals business revenue in Q3FY26 grew by 19.4% YoY to INR 19.4bn, supported by a 14.3% increase in occupied beds to 3,189 beds in Q3FY26 compared to 2,790 beds in Q3FY25.
- ▶ ARPOB stood at INR 25.6mn per annum, up 4.5% YoY (vs INR 24.5mn in Q3FY25), while the occupancy level remains at 67%. Robotics surgery grew by 52% YoY.
- ▶ International patient revenue grew 19% YoY to ~INR 1.6bn, contributing 7.7% of hospitals revenue (vs 7.7% in Q2FY25).
- ▶ Focus specialties – oncology, neurosciences, cardiac sciences, gastroenterology, orthopedics, and renal sciences – grew 19% YoY, contributing 61% of hospitals revenue.
- ▶ Digital channels (website, app, and campaigns) reported 18.9% YoY growth, contributing 29.8% to hospitals revenue (vs. 29.9% in Q3FY25).
- ▶ Occupied beds increased 14.3% QoQ to 3,189 in Q3FY26 (vs. 2,790 in Q3FY25).
- ▶ ALOS stood at 4.29 days in Q3FY26 compared to 4.2 days in Q3FY25.
- ▶ The company further strengthened its medical talent with the onboarding of specialists in the areas of oncology, neurosciences and general surgery.
- ▶ Thirteen hospitals achieved EBITDA margin of >20%, collectively contributing 77% of total hospitals revenue.


### Diagnostics business

- ▶ The diagnostics business reported gross revenue of INR 3.7bn in Q3FY26, up 8.3% YoY, from INR 3.4bn in Q3FY25.
- ▶ Net revenue for the quarter stood at ~INR 3.3bn, up by 7% YoY.
- ▶ Operating EBITDA margin (on gross revenue) improved to 23.1% vs 14.4% in Q3FY25. Excluding one-offs, operating EBITDA margin stood at 21.3% in Q3FY25.
- ▶ Continuing its network expansion, Agilus increased its customer touchpoints (CTP) to 4,370 as on 31 December 2025.
- ▶ The business conducted ~9.9mn tests during the quarter, up from ~9.6mn in Q3FY25.
- ▶ The preventive health portfolio contributed 12% to overall diagnostics revenue vs 10% in Q3FY25.
- ▶ Geographically, North India contributed 29%, South India 34%, West India 20%, East India 12%, and international markets 5% to total revenue.
- ▶ By product mix, routine tests contributed 53%, specialized 35%, and wellness 12% during Q3FY26.
- ▶ B2C to B2B mix stood at 52% and 48%, respectively.

### Guidance

- ▶ People Tree Hospital is running at sub-optimal level. The facility will need investment to improve margin to reach FORH level. Brownfield expansion on the adjacent land will commence soon and is expected to be completed in the next 24-30 months.
- ▶ The Manesar facility generates revenue of INR 150mn per month and is EBITDA-positive. Oncology block work has started for the facility.
- ▶ The NagerBhavi facility currently operates EBITDA of upward of 20%.
- ▶ Gleneagles Hospital is currently in the integration process. During the quarter, the facility generated revenue of ~INR 1.7bn with an EBITDA margin of 3% after absorbing 3% fees.
- ▶ Existing units grew by 15% YoY whereas new units grew by ~4% YoY during the quarter.
- ▶ The Jalandhar facility is operating at 25% EBITDA whereas the occupancy level of Mulund facility is 65%.

- ▶ ARPOB is set to grow by 4-5% yoy, driven by 2.0-2.5% price hike and the remaining from case mix in FY27.
- ▶ During 9MFY26, the company added 750 beds with 500 added through acquisitions and 250 through Brownfield across Noida, Faridabad, and Manesar.
- ▶ FMRI new block is set to commence in April 2026.
- ▶ Occupancy level during the quarter witnessed 50bp, drag due to challenges in new units.
- ▶ The company is planning to add 430 beds largely through Brownfield additions at the FMRI facility with 220 beds, which will be operationalized in a phased manner with 100-120 beds in FY26.

**Exhibit 3: Currently trading at a 20% premium to its long-term average of 24.2x on a rolling EV/EBITDA**



Source: Company, Bloomberg, Elara Securities Estimate

**Exhibit 4: Change in estimates**

(INR mn)	Old			Revised			% change		
	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E
Sales	91,277	1,05,088	1,16,425	91,172	1,05,216	1,16,544	(0.1)	0.1	0.1
EBITDA	21,289	25,100	28,224	21,102	24,945	28,039	(0.9)	(0.6)	(0.7)
PAT	11,260	14,115	16,702	10,467	13,467	16,047	(7.0)	(4.6)	(3.9)
EPS (INR)	13.8	18.1	21.5	13.4	17.3	20.7	(3.0)	(4.5)	(3.9)
Rating	Accumulate			Reduce					

Source: Elara Securities Estimate

## Coverage History



Date	Rating	Target Price (INR)	Closing Price (INR)
24-May-2023	Buy	349	288
22-Jun-2023	Buy	372	309
04-Aug-2023	Accumulate	372	339
10-Nov-2023	Accumulate	390	359
08-Feb-2024	Accumulate	488	441
07-Aug-2024	Accumulate	541	486
08-Nov-2024	Accumulate	661	621
10-Feb-2025	Accumulate	686	627
21-May-2025	Accumulate	749	672
06-Aug-2025	Accumulate	927	858
16-Feb-2026	Reduce	927	917

## Guide to Research Rating

<b>BUY (B)</b>	Absolute Return >+20%
<b>ACCUMULATE (A)</b>	Absolute Return +5% to +20%
<b>REDUCE (R)</b>	Absolute Return -5% to +5%
<b>SELL (S)</b>	Absolute Return < -5%

## Disclosures & Confidentiality for non U.S. Investors

The Note is based on our estimates and is being provided to you (herein referred to as the "Recipient") only for information purposes. The sole purpose of this Note is to provide preliminary information on the business activities of the company and the projected financial statements in order to assist the recipient in understanding / evaluating the Proposal. Nothing in this document should be construed as an advice to buy or sell or solicitation to buy or sell the securities of companies referred to in this document. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved) and should consult its own advisors to determine the merits and risks of such an investment. Nevertheless, Elara Securities (India) Private Limited or any of its affiliates is committed to provide independent and transparent recommendation to its client and would be happy to provide any information in response to specific client queries. Elara Securities (India) Private Limited or any of its affiliates have not independently verified all the information given in this Note and expressly disclaim all liability for any errors and/or omissions, representations or warranties, expressed or implied as contained in this Note. The user assumes the entire risk of any use made of this information. Elara Securities (India) Private Limited or any of its affiliates, their directors and the employees may from time to time, effect or have effected an own account transaction in or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for or solicit investment banking or other business from any company referred to in this Note. Each of these entities functions as a separate, distinct and independent of each other. This Note is strictly confidential and is being furnished to you solely for your information. This Note should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose. This Note is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject Elara Securities (India) Private Limited or any of its affiliates to any registration or licensing requirements within such jurisdiction. The distribution of this document in certain jurisdictions may be restricted by law, and persons in whose possession this document comes, should inform themselves about and observe, any such restrictions. Upon request, the Recipient will promptly return all material received from the company and/or the Advisors without retaining any copies thereof. The Information given in this document is as of the date of this report and there can be no assurance that future results or events will be consistent with this information. This Information is subject to change without any prior notice. Elara Securities (India) Private Limited or any of its affiliates reserves the right to make modifications and alterations to this statement as may be required from time to time. However, Elara Securities (India) Private Limited is under no obligation to update or keep the information current. Neither Elara Securities (India) Private Limited nor any of its affiliates, group companies, directors, employees, agents or representatives shall be liable for any damages whether direct, indirect, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. This Note should not be deemed an indication of the state of affairs of the company nor shall it constitute an indication that there has been no change in the business or state of affairs of the company since the date of publication of this Note. The disclosures of interest statements incorporated in this document are provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. Elara Securities (India) Private Limited generally prohibits its analysts, persons reporting to analysts and their family members from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Any clarifications / queries on the proposal as well as any future communication regarding the proposal should be addressed to Elara Securities (India) Private Limited. It is important to note that any dispute with respect to this research report, would not have access to stock exchange investor redressal forum or arbitration mechanism.

Elara Securities (India) Private Limited was incorporated in July 2007 as a subsidiary of Elara Capital (India) Private Limited.

Elara Securities (India) Private Limited is a SEBI registered Stock Broker in the Capital Market and Futures & Options Segments of National Stock Exchange of India Limited [NSE] and BSE Limited [BSE] and a Depository Participant registered with Central Depository Services (India) Limited [CDSL].

Elara Securities (India) Private Limited's business, amongst other things, is to undertake all associated activities relating to its broking business.

The activities of Elara Securities (India) Private Limited were neither suspended nor has it defaulted with any stock exchange authority with whom it is registered in last five years. However, during the routine course of inspection and based on observations, the exchanges have issued advise letters or levied minor penalties on Elara Securities (India) Private Limited for minor operational deviations in certain cases. Elara Securities (India) Private Limited has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has the certificate of registration been cancelled by SEBI at any point of time.

Elara Securities (India) Private Limited offers research services primarily to institutional investors and their employees, directors, fund managers, advisors who are registered or proposed to be registered.

Details of Associates of Elara Securities (India) Private Limited are available on group company website [www.elaracapital.com](http://www.elaracapital.com)

Elara Securities (India) Private Limited is maintaining arms-length relationship with its associate entities.

Research Analyst or his/her relative(s) may have financial interest in the subject company. Elara Securities (India) Private Limited does not have any financial interest in the subject company, whereas its associate entities may have financial interest. Research Analyst or his/her relative does not have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report. Elara Securities (India) Private Limited does not have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report. Associate entities of Elara Securities (India) Private Limited may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report. Research Analyst or his/her relative or Elara Securities (India) Private Limited or its associate entities does not have any other material conflict of interest at the time of publication of the Research Report.

Artificial Intelligence (AI) tools may have been used only for compilation or collating publicly available research data or internally generated research data during the information gathering and/or summarizing the final report.

Research Analyst or his/her relative(s) has not served as an officer, director or employee of the subject company.

Research analyst or Elara Securities (India) Private Limited have not received any compensation from the subject company in the past twelve months. Associate entities of Elara Securities (India) Private Limited may have received compensation from the subject company in the past twelve months. Research analyst or Elara Securities (India) Private Limited or its associate entities have not managed or co-managed public offering of securities for the subject company in the past twelve months. Research analyst or Elara Securities (India) Private Limited or its associates have not received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months. Research analyst or Elara Securities (India) Private Limited or its associate entities may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company or third party in connection with the Research Report in the past twelve months.

## Disclaimer & Standard warning

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

## Disclaimer for non U.S. Investors

The information contained in this note is of a general nature and is not intended to address the circumstances of any particular individual or entity. Although we endeavor to provide accurate and timely information, there can be no guarantee that such information is accurate as of the date it is received or that it will continue to be accurate in the future. No one should act on such information without appropriate professional advice after a thorough examination of the particular situation.



## Disclosures for U.S. Investors

**Rule 15a6 Disclosure:** This research report ("Report") was prepared, approved, published, and distributed by Elara Securities (India) Private Limited a company located outside of the United States (the "**Foreign Counterparty**"). Avior Capital Markets US LLC ("**Avior US**"), a US registered broker-dealer, distributes this Report in the US on behalf of the Foreign Counterparty. Only major U.S. institutional investors (as defined in Rule 15a-6 under the US Securities Exchange Act of 1934 (the "**Exchange Act**") may receive this Report under the exemption in Rule 15a-6. A US institutional investor must effect any transaction in the securities described in this Report through Avior US.

Neither the Report nor any analyst who prepared or approved the Report is subject to US legal requirements or the Financial Industry Regulatory Authority, Inc. ("**FINRA**") or other US regulatory requirements concerning research reports or research analysts. The Foreign Counterparty is not a registered broker-dealer under the Exchange Act nor is it a member of the Financial Industry Regulatory Authority, Inc., or any other US self-regulatory organisation.

**Disclosures on Subject Companies:** Analysts of the Foreign Counterparty produced this material solely for informational purposes and the use of the intended recipient. No person may reproduce, this Report under any circumstances. No person may copy or make this Report available to any other person other than the intended recipient.

Avior US distributes this Report in the United States of America. The Foreign Counterparty distributes this Report elsewhere in the world. This document is not an offer, or invitation by or on behalf of Avior US, the Foreign Counterparty, their affiliates, or any other person, to buy or sell any security.

Avior US and the Foreign Counterparty and their affiliates obtained the information contained herein from published information and other sources, which Avior US and the Foreign Counterparty and their affiliates reasonably consider to be reliable.

Avior US and the Foreign Counterparty accept no liability or responsibility whatsoever for the accuracy or completeness of any such information. All estimates, expressions of opinion and other subjective judgments contained herein are valid as of the date of this document. Avior US assumes responsibility for the Report content with regards to research distributed in the US.

Neither Avior US nor the Foreign Counterparty has managed or co-managed a public offering of securities for the subject company in the past 12 months, have not received compensation for investment banking services from the subject company in the past 12 months and do not expect to receive and does not intend to seek compensation for investment banking services from the subject company in the next three months. Avior US and the Foreign Counterparty have not owned any class of equity securities of the subject company. There are no other actual, material conflicts of interest of Avior US and the Foreign Counterparty at the time of the publication of this Report. As of the publication of this Report, Avior US nor the Foreign Counterparty makes a market in the subject securities.

Avior US and its affiliates, to the fullest extent permissible by law, accept no liability of any nature whatsoever for any claims, damages or losses arising from, or in connection with, the contents of this Report or the use, reliance, publication, distribution, dissemination, disclosure, alteration or reproduction of this Report, or any views or recommendations recorded therein.

Participants in foreign exchange transactions may incur risks arising from several factors, including the following: (i) exchange rates can be volatile and are subject to large fluctuations; (ii) the value of currencies may be affected by numerous market factors, including world and national economic, political and regulatory events, events in equity and debt markets and changes in interest rates; and (iii) currencies may be subject to devaluation or government imposed exchange controls which could affect the value of the currency. Investors in securities such as ADRs, whose values are affected by the currency of an underlying security, effectively assume currency risk.

Subject to the applicable laws, all transactions should be executed through Avior US. Aside from within this Report, important conflict disclosures can also be found at <https://aviorcapital.us/us-regulatory-disclosures/> and Investors are strongly encouraged to review this information before investing.

## Additional Disclaimer for UK Investors

Note that Elara Securities (India) Private Limited ("**Foreign Counterparty**") has concluded a MiFID II research intermediary agreement with Avior Capital Markets International Limited ("**Avior UK**"), regulated by the Financial Conduct Authority (FRN: 191074), pursuant to which Avior UK distributes the Foreign Counterparty's research in the UK, in return for which the Foreign Counterparty pays Avior UK a percentage of the income received in relation to such research. This research report including any recommendations recorded therein ("**Report**") have been prepared by the Foreign Counterparty, and not by Avior UK.

The Report: (a) has been objectively prepared from public sources which are believed to be reliable and therefore constitutes independent investment research and is presented as such; and (b) may only be distributed to, and relied on by, qualifying investors, who are permitted to receive same in the UK.

Securities, money market instruments, strategies, financial or investment instruments mentioned in this Report may not be suitable for all investors. The information and opinions provided in this Report do not constitute a personal recommendation/investment advice and take no account of the investor's individual circumstances. Investors should consider this Report as only a single factor in making any investment decisions and, if appropriate, should seek advice from an investment advisor. This Report is not an offer, or invitation by or on behalf of Avior UK, the Foreign Counterparty, their affiliates, or any other person, to buy or sell any security.

Save as disclosed otherwise, the Foreign Counterparty's relationship with Avior UK is not reasonably expected to impair the objective presentation of the recommendations in the Report, including any interests or conflicts of interest concerning any financial instruments or the issuers to which the recommendations, directly or indirectly, relate. The Report is deemed to be first disseminated at the date and time recorded on the relevant distribution platform, data network or email (as applicable), and which information is available on request. A list of the Foreign Counterparty's research reports disseminated in the UK over the past 12 months is also available on request.

Avior UK does not assume any responsibility or liability of any nature whatsoever arising from or in connection with the content, use, reliance or dissemination of the Report or any recommendation in respect thereof and disclaims any such liability.

## Certification by Each of the Authors of this Report

The analyst(s) (singular includes plural) ("Analyst") certifies that the views expressed in this Report are an accurate representation of the Analyst's personal opinions on the stock or sector as covered and reported on by the Analyst hereinabove. The Analyst furthermore certifies that no part of the Analyst's compensation was, is, or will be related, directly or indirectly, to the specific recommendations or views as expressed in this document. The Analyst is principally responsible for the preparation of this Report and does not have any material conflict of interest at the time of publication of this Report. The Analyst(s) has not served as an officer, director or employee of the subject company in the last 12-month period ending on the last day of the month immediately preceding the date of publication of the Report.

**Analyst Certification:** In connection with the companies or securities that; each analyst identified in this Report certifies that: The views expressed on the subject companies and securities in this Report reflect their personal views. No part of his or her compensation was, is or will be directly or indirectly dependent on the specific recommendations or views expressed in this Report.

Note that:

- (i) The Foreign Counterparty is the employer of the research analyst(s) responsible for the content of this Report, and
- (ii) Research analysts preparing this Report are resident outside the United States and are not associated persons of any US regulated broker-dealer. Therefore, the analyst(s) are not subject to supervision by a US broker-dealer and are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with US rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.



**Avior Capital Markets US, LLC** is a FINRA registered broker-dealer (CRD # 172595) formed for that purpose in the State of Delaware with its principal office at 45 Rockefeller Plaza, Suite 2335, New York, New York 10111.

**Avior Capital Markets International Limited** is regulated by the Financial Conduct Authority (FRN: 191074), with its principal office at 10 South Street, Elgin, Scotland IV30 1LE.

**Elara Securities (India) Private Limited** is a SEBI-registered Research Analyst (Regn. No.: INH000000933), Stock Broker (Regn. No.: INZ000238236) and Depository Participant (Regn. No.: IN-DP-370-2018). Its registered address is One International Center, Tower 3, 21st Floor, Senapati Bapat Marg, Elphinstone Road (West) Mumbai – 400 013, India



<b>India</b> <b>Elara Securities (India) Private Limited</b> One International Center, Tower 3, 21st Floor, Senapati Bapat Marg, Elphinstone Road (West) Mumbai – 400 013, India Tel : +91 22 6164 8500	<b>Europe</b> <b>Elara Capital Plc.</b> 6th Floor, The Grove, 248A Marylebone Road, London, NW1 6JZ, United Kingdom Tel : +44 20 7486 9733	<b>USA</b> <b>Elara Securities Inc.</b> 230 Park Avenue, Suite 2415, New York, NY 10169, USA Tel: +1 212 430 5870 Fax: +1 212 208 2501	<b>Asia / Pacific</b> <b>Elara Capital (Asia) Pte.Ltd.</b> One Marina Boulevard, Level 20, Singapore 018989 Tel : +65 6978 4047
---	--	---	--

	<b>Managing Director</b> <b>Harendra Kumar</b>   harendra.kumar@elaracapital.com   +91 22 6164 8571
	<b>Head of Research</b> <b>Dr Bino Pathiparampil</b>   bino.pathiparampil@elaracapital.com   +91 22 6164 8572

## Sales Team

	<b>India</b> <b>Hitesh Danak</b> - hitesh.danak@elaracapital.com - +91 22 6164 8543 <b>Ashok Agarwal</b> - ashok.agarwal@elaracapital.com - +91 22 6164 8558 <b>Himani Sanghavi</b> - himani.sanghavi@elaracapital.com - +91 22 6164 8586
	<b>India, APAC &amp; Australia</b> <b>Sudhanshu Rajpal</b> - sudhanshu.rajpal@elaracapital.com - +91 22 6164 8508 <b>Joshua Saldanha</b> - joshua.saldanha@elaracapital.com - +91 22 6164 8541 <b>Shraddha Shrikhande</b> - shraddha.shrikhande@elaracapital.com - +91 22 6164 8567 <b>Suyash Maheshwari</b> - suyash.maheshwari@elaracapital.com - +91 22 4204 8698
	<b>India &amp; UK</b> <b>Prashin Lalvani</b> - prashin.lalvani@elaracapital.com - +91 22 6164 8544
	<b>India &amp; US</b> <b>Karan Rathod</b> - karan.rathod@elaracapital.com - +91 22 6164 8570
	<b>Corporate Access, Conference &amp; Events</b> <b>Anita Nazareth</b> - anita.nazareth@elaracapital.com - +91 22 6164 8520 <b>Tina D'souza</b> - tina.dsouza@elaracapital.com - +91 22 6164 8595

By clicking this link, you acknowledge and agree to the [Terms and Conditions of Research Services](#)

Access our reports on Bloomberg: Type **RESP ESEC &ltGO>**

Also available on **Thomson & Reuters**

### Elara Securities (India) Private Limited

Registered Office Address: One International Center, Tower 3, 21st Floor, Senapati Bapat Marg, Elphinstone Road (West) Mumbai – 400 013, India Tel : +91 22 6164 8500  
CIN: U74992MH2007PTC172297 | SEBI Research Analyst Registration No.: INH000000933  
Member of BSE Limited and National Stock Exchange of India Limited | SEBI REGN. NO.: INZ000238236  
Member of Central Depository Services (India) Limited | SEBI REGN. NO.: IN-DP-370-2018  
Investor Grievance Email ID: [investor.grievances@elaracapital.com](mailto:investor.grievances@elaracapital.com) - Tel. +91 22 6164 8509  
Compliance Officer: Mr. Anand Rao - Email ID: [anand.rao@elaracapital.com](mailto:anand.rao@elaracapital.com) - Tel. +91 22 6164 8509